Clinical Trial Trends: Rare Oncology

The ongoing increase in rare oncology cases worldwide puts a spotlight on the need for effective treatment protocols. In this article, we will explore a variety of rare oncology clinical trials, including the number of trials, their geographical spread, phases, and the specific patient segments they target. 

Current State of Rare Oncology Clinical Trials

In this section, we will take a detailed look into the rare oncology clinical trial environment, underpinned by extensive data from Citeline.  

Rare Oncology Clinical Trials by Status  

Out of the almost 60,000 recorded rare oncology trials, over 29% are active (open or planned), highlighting an aggressive pursuit of new therapies.  

Rare Oncology Trials by Status 

Citeline Trialtrove^® – 30JUN2024
 

Rare Oncology Trials by Start Date  

Rare oncology trials have seen a steady increase in their initiation over the past years, showcasing active research development. 

Planned & Ongoing Rare Oncology Trials by Start Date 

Citeline Trialtrove^® – 30MAY2024 

Rare Oncology Trials by Country  

Significant global participation is evident in rare oncology trials, with 109 countries involved, each contributing to a broader understanding of the disease. 

Planned & Ongoing Rare Oncology Trials by Site Country 

Citeline Trialtrove^® – 30JUN2024 

Rare Oncology Trials by Indication 

Therapeutic coverage in rare oncology clinical trials is extensive, with significant representation in solid tumors and blood cancers. 

Planned & Ongoing Rare Oncology Trials by Indication 

Citeline Trialtrove^® – 30JUN2024 

Rare Oncology Trials by Phase  

With 4,717 trials in Phase 1, 2,263 in Phase 1-2, and another 7,283 in Phase 2, the rare oncology clinical trial environment demonstrates a strong inclination towards early therapeutic evaluation. 

Planned & Ongoing Rare Oncology Trials by Phase 

Citeline Trialtrove^® – 30JUN2024 

Precision's Expertise in Rare Oncology Research  

Precision for Medicine's influence in rare oncology research is marked by 237 trials that span early discovery to late-stage development. 

Rare Oncology Trial Starts  

Since 2002, Precision for Medicine has been running trials for rare oncology indications, underlining our commitment to be involved in effective therapeutic solutions. 

Precision for Medicine's Rare Oncology Trials by Start Date 

Citeline Trialtrove^® – 30JUN2024 

Precision's Reach in Rare Oncology Research  

We conduct rare oncology research in 60 countries, each site chosen for its strategic importance to global health trends and local disease prevalence. 

Precision for Medicine's Rare Oncology Trials by Site Country 

Citeline Trialtrove^® – 30JUN2024 

Rare Oncology Trials by Phase  

Precision for Medicine has worked extensively in early-phase rare oncology research, with over 200 Phase 1, 1-2, and 2 trials out of 237. 

Precision for Medicine's Rare Oncology Trials by Phase 

Citeline Trialtrove^® – 30JUN2024 

Precision's Experience by Indication 

Our rare oncology experience is varied, with our experience within the rare hematological oncology space comprising a significant portion of our historical portfolio of work. 

Precision for Medicine’s Rare Oncology Trials by Segment 

Chart Caption: Citeline Trialtrove^® – 30JUN2024 

Discover the Precision Difference

Success in rare oncology research demands a level of expertise and dedication that sets a Clinical Research Organization (CRO) apart. With the stakes high and the landscape constantly shifting, selecting the right CRO partner is a critical decision that can shape the course of your study. Our deep understanding of the unique challenges posed by rare oncology trials, coupled with our unwavering focus on patient-centric solutions and innovative methodologies, positions us as the premier choice for guiding your rare oncology research endeavors. 

Breaking new ground in the realm of rare oncology, our mission remains clear: to make a profound impact on the development of innovative therapies, ultimately offering hope and improved quality of life to patients facing rare cancers across the globe.